| Identification | Back Directory | [Name]
TDN 345 | [CAS]
134069-68-4 | [Synonyms]
TDN 345
1-Oxa-3,8-diazaspiro[4.5]decan-2-one, 8-[4,4-bis(4-fluorophenyl)butyl]-3-(1,1-dimethylethyl)-4-methylene- | [Molecular Formula]
C28H34F2N2O2 | [MDL Number]
MFCD00899631 | [MOL File]
134069-68-4.mol | [Molecular Weight]
468.58 |
| Chemical Properties | Back Directory | [Boiling point ]
556.2±60.0 °C(Predicted) | [density ]
1.18±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [pka]
9.67±0.20(Predicted) |
| Hazard Information | Back Directory | [Uses]
TDN345 is a Ca2+ antagonist, used for the treatment of vascular and senile dementia including Alzheimer's disease. | [in vivo]
TDN-345 (0.1-1.0 mg/kg, p.o.) dose-dependently decreases the mortality and ischemic neurological deficit score when administered orally twice, 60 min before ischemia and 90 min after recirculation. Additionally, TDN-345 (0.2 or 1.0 mg/kg, p.o. once daily for 3 weeks after the onset of stroke) decreases the mortality and recurrence of stroke in SHRSP[2]. | [References]
[1] Fukumoto H, et al. The novel compound TDN-345 induces synthesis/secretion of nerve growth factor in C6-10A glioma cells. Brain Res. 1997 Nov 7;774(1-2):87-93. DOI:10.1016/s0006-8993(97)81691-5
[2] Nakayama T, et al. Beneficial effects of TDN-345, a novel Ca2+ antagonist, on ischemic brain injury and cerebral glucose metabolism in experimental animal models with cerebrovascular lesions. Brain Res. 1997 Jul 11;762(1-2):203-10. DOI:10.1016/s0006-8993(97)00388-0 |
|
|